X4 Pharmaceuticals Future Growth
Future criteria checks 2/6
X4 Pharmaceuticals's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 38.4% per year. EPS is expected to grow by 11.7% per annum.
Key information
-4.1%
Earnings growth rate
11.70%
EPS growth rate
| Biotechs earnings growth | 23.8% |
| Revenue growth rate | 38.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 10 Jun 2025 |
Recent future growth updates
Recent updates
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 113 | -50 | -82 | N/A | 5 |
| 12/31/2026 | 23 | -101 | -68 | N/A | 6 |
| 12/31/2025 | 35 | -77 | N/A | N/A | 5 |
| 3/31/2025 | 31 | 15 | -120 | -110 | N/A |
| 12/31/2024 | 3 | -37 | -138 | -131 | N/A |
| 9/30/2024 | 1 | -17 | -133 | -126 | N/A |
| 6/30/2024 | 1 | 18 | -120 | -112 | N/A |
| 3/31/2024 | N/A | -129 | -104 | -104 | N/A |
| 12/31/2023 | N/A | -101 | -97 | -97 | N/A |
| 9/30/2023 | N/A | -111 | -88 | -88 | N/A |
| 6/30/2023 | N/A | -131 | -86 | -86 | N/A |
| 3/31/2023 | N/A | -96 | -83 | -83 | N/A |
| 12/31/2022 | N/A | -96 | -77 | -77 | N/A |
| 9/30/2022 | N/A | -103 | -77 | -77 | N/A |
| 6/30/2022 | N/A | -102 | -72 | -72 | N/A |
| 3/31/2022 | N/A | -100 | -73 | -73 | N/A |
| 12/31/2021 | N/A | -103 | -72 | -71 | N/A |
| 9/30/2021 | N/A | -85 | -70 | -69 | N/A |
| 6/30/2021 | N/A | -82 | -71 | -69 | N/A |
| 3/31/2021 | N/A | -78 | -63 | -62 | N/A |
| 12/31/2020 | 3 | -62 | -60 | -59 | N/A |
| 9/30/2020 | 3 | -55 | -52 | -51 | N/A |
| 6/30/2020 | 3 | -55 | -50 | -49 | N/A |
| 3/31/2020 | 3 | -53 | -53 | -52 | N/A |
| 12/31/2019 | N/A | -53 | -48 | -48 | N/A |
| 9/30/2019 | N/A | -55 | -46 | -46 | N/A |
| 6/30/2019 | N/A | -46 | -40 | -39 | N/A |
| 3/31/2019 | N/A | -40 | -31 | -31 | N/A |
| 12/31/2018 | N/A | -36 | N/A | -25 | N/A |
| 9/30/2018 | N/A | -31 | N/A | -23 | N/A |
| 12/31/2017 | N/A | -25 | N/A | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XFOR's earnings are forecast to decline over the next 3 years (-4.1% per year).
Earnings vs Market: XFOR's earnings are forecast to decline over the next 3 years (-4.1% per year).
High Growth Earnings: XFOR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: XFOR's revenue (38.4% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: XFOR's revenue (38.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XFOR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/15 05:16 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |